Login to Your Account



Bluebird Bio, Celgene Hatch Gene Therapy Collaboration

By Marie Powers
Staff Writer

Friday, March 22, 2013
Privately held gene therapy company bluebird bio soared to new heights in a discovery, development and commercialization deal with big biotech Celgene Corp. to use its technology to genetically modify a patient's own T cells to target and destroy cancer cells. The multiyear R&D collaboration has the potential to generate multiple products based on the modified cells, known as chimeric antigen receptor (CAR) T cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription